U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Development & Approval Process (CBER)
  4. 2023 Biological License Application Approvals
  1. Development & Approval Process (CBER)

2023 Biological License Application Approvals

This list reflects information regarding the applications as of the approval date. It is not updated with regard to applicant or application status changes. The applications are listed by date of approval in reverse chronological order.

2023 Biological License Application Approvals
Tradename/Proper Name Indication for Use STN Manufacturer/
License Number
Approval Date
ABRYSVO
Respiratory Syncytial Virus Vaccine
Indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. 125768/0 Pfizer Inc.
500 Arcola Road
Collegeville, PA 19426

Lic. # 2001
08/21/2023
BALFAXAR
prothrombin complex concentrate, human-lans
Indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure. 125776/0 Octapharma Pharmazeutika Produktionsges.m.b.H.
Octapharma USA, Inc.
117 West Century Road
Paramus, NJ 07652

Lic. # 1646
07/21/2023
CYFENDUS
Anthrax Vaccine Adsorbed, Adjuvanted
Indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. 125761/0 Emergent Product Development Gaithersburg Inc.
300 Professional Drive
Gaithersburg, MD 20879

Lic. # 2089
07/20/2023
ROCTAVIAN
valoctocogene roxaparvovec-rvox
Valoctocogene roxaparvovec-rvox is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity <1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. 125720/0 BioMarin Pharmaceutical Inc.
105 Digital Drive
Novato, CA 94949

Lic. # 1649
06/29/2023
LANTIDRA
donislecel-jujn
Indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. 125734/0 CellTrans Inc.
2201 W. Campbell Park Drive, Suite 23
Chicago, IL 60612

Lic. # 2213
06/28/2023
ELEVIDYS
delandistrogene moxeparvovec-rokl
Indicated for treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. 125781/0 Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA 02142

Lic. # 2308
06/22/2023
Elecsys HIV Duo
Elecsys HIV Duo
Elecsys HIV Duo is intended to screen individual human donors, including volunteer donors of whole blood, blood components and source plasma. The assay is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor's heart is still beating. It is not intended for use on cord blood specimens. 125778/0 Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250

Lic. # 2305
06/13/2023
ABRYSVO
Respiratory Syncytial Virus Vaccine
Indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. 125769/0 Pfizer Inc.
500 Arcola Road
Collegeville, PA 19426

Lic. # 2001
05/31/2023
VYJUVEK
beremagene geperpavec-svdt
Indicated for treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. 125774/0 Krystal Biotech, Inc.
2100 Wharton Street, Suite 701
Pittsburgh, PA 15203

Lic. # 2301
05/19/2023
AREXVY
Respiratory Syncytial Virus Vaccine, Adjuvanted
Indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. 125775/0 GlaxoSmithKline Biologicals
14200 Shady Grove Road
Rockville, MD 20850

Lic. # 1617
05/03/2023
VOWST
fecal microbiota spores, live-brpk
To prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). 125757/0 Seres Therapeutics, Inc.
200 Sidney Street
Cambridge, MA 02139

Lic. # 2262
04/26/2023
OMISIRGE
omidubicel-onlv
Indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. 125738/0 Gamida Cell Ltd.
116 Huntington Ave., 7th floor
Boston, MA 02116

Lic. # 2223
04/17/2023
Source Plasma Indicated for further manufacturing of injectable and non-injectable products. 125790/0 Clinical Research Technologies, Inc. (CRT)
1068 Broadway
El Cajon, CA 92021

Lic. # 2316
02/23/2023
ALTUVIIIO
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Indicated for use in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding. 125771/0 Bioverativ Therapeutics, Inc.
55 Corporate Drive
Bridgewater, NJ 08807

Lic. # 2078
02/22/2023
Source Plasma Indicated for further manufacturing of injectable products 125762/0 Join Parachute, LLC
210 Barton Springs Drive, #550
Austin, TX 78704

Lic. # 2273
01/25/2023
Source Plasma Indicated for further manufacturing of injectable and noninjectable products 125767/0 Olgam Life LLC
1104 Fulton Street
Brooklyn, NY 11238

Lic. # 2287
01/19/2023
Source Plasma Indicated for further manufacturing of injectable products 125765/0 Pelican Plasma
8910 Linwood Avenue
Shreveport, LA 71106

Lic. # 2283
01/17/2023

 

Back to Top